The International Agency for Research on Cancer (IARC) classified arsenic, a toxic metalloid, as a group 1 carcinogen \> 20 years ago ([@b47-ehp-119-11]). It is widely accepted that exposure to arsenic is associated with lung, bladder, kidney, liver, and nonmelanoma skin cancers ([@b48-ehp-119-11]; [@b89-ehp-119-11]; [@b110-ehp-119-11]; [@b112-ehp-119-11]). High levels of arsenic have also been associated with the development of several other diseases and deleterious health effects in humans, such as skin lesions (dyspigmentation, keratosis), peripheral vascular diseases, reproductive toxicity, and neurological effects ([@b1-ehp-119-11]).

Exposure to arsenic typically results from either oral arsenic consumption through contaminated drinking water, soil, and food, or arsenic inhalation in an industrial work setting. Arsenic-contaminated drinking water has been associated with increased mortality of bladder and lung cancer in Chile ([@b72-ehp-119-11]) and with increased mortality of both noncancerous causes and cancers in Bangladesh ([@b113-ehp-119-11]). In the human arsenic metabolic pathway, inorganic pentavalent arsenic (As^V^) is converted to trivalent arsenic (As^III^), with subsequent methylation to monomethylated and dimethylated arsenicals (MMA, DMA, respectively) ([@b30-ehp-119-11]). The general scheme is as follows:
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Methylated arsenicals, especially MMA^III^, are considered more toxic than inorganic As^III^ both *in vivo* (in animals) ([@b91-ehp-119-11]) and *in vitro* (human cell lines) ([@b115-ehp-119-11]). Several mechanisms by which arsenical compounds induce tumorigenesis have been proposed, including oxidative stress ([@b61-ehp-119-11]), genotoxic damage and chromosomal abnormalities ([@b82-ehp-119-11]; [@b130-ehp-119-11]), and cocarcinogenesis with other environmental toxicants ([@b101-ehp-119-11]); epigenetic mechanisms, in particular, have been reported to alter DNA methylation ([@b131-ehp-119-11]).

It is generally believed that arsenic does not induce point mutations, based on negative findings in both bacterial and mammalian mutagenicity assays ([@b51-ehp-119-11]; [@b58-ehp-119-11]). Arsenic does induce deletion mutations, but arsenical compounds vary in their potency ([@b83-ehp-119-11]). With respect to arsenic's ability to induce chromosomal alterations in humans, studies in the early 1990s showed that the cell micronucleus assay could be used as a biological marker of the genotoxic effects of arsenic exposure ([@b111-ehp-119-11]). Later studies validated this assay and demonstrated higher frequencies of micronuclei in individuals who were chronically exposed to arsenicals ([@b82-ehp-119-11]). Analysis of chromosomal alterations in DNA from bladder tumors of 123 patients who had been exposed to arsenic in drinking water showed that tumors from patients with higher estimated levels of arsenic exposure had higher levels of chromosomal instability than did tumors from patients with lower estimated levels of exposure, suggesting that bladder tumors from arsenic-exposed patients may behave more aggressively than do tumors from unexposed patients ([@b81-ehp-119-11]). Based on these overall findings, a plausible and generally accepted mechanism for arsenic carcinogenicity is the induction of structural and numerical chromosomal abnormalities through indirect effects on DNA. However, as has been demonstrated for several tumors, including urothelial and hematological malignancies ([@b36-ehp-119-11]; [@b84-ehp-119-11]), it is likely that interrelated genetic and epigenetic mechanisms together contribute to the toxicity and carcinogenicity of arsenic ([@b45-ehp-119-11]; [@b131-ehp-119-11]).

Epigenetic Modifications Induced by Arsenic
===========================================

Epigenetic alteration, which is not a genotoxic effect, leads to heritable phenomena that regulate gene expression without involving changes in the DNA sequence ([@b34-ehp-119-11]) and thus could be considered a form of potentially reversible DNA modification. Recent mechanistic studies of arsenic carcinogenesis have directly or indirectly shown the potential involvement of altered epigenetic regulation in gene expression changes induced by arsenic exposure. We recently showed that urinary defensin, beta 1 (DEFB1) protein levels were significantly decreased among men highly exposed to arsenic in studies conducted in Nevada (USA) and in Chile ([@b44-ehp-119-11]). DNA methylation is thought to play a role in regulating *DEFB1* expression ([@b116-ehp-119-11]). Follow-up studies are under way in our laboratory to determine if reduced levels of DEFB1 in exposed populations are due to arsenic-induced targeted gene silencing. Several studies have observed extensive changes in global gene expression in individuals after arsenic exposure ([@b3-ehp-119-11]; [@b7-ehp-119-11]; [@b12-ehp-119-11]; [@b124-ehp-119-11]). Further, maternal exposure to arsenic has been shown to alter expression of transcripts in the mouse fetus ([@b67-ehp-119-11]) and human newborn ([@b37-ehp-119-11]). Because epigenetic processes are major regulators of gene expression, these findings suggest that dysregulation of epigenetic processes could contribute mechanistically to arsenic-induced changes in gene expression and cancer, affecting both people exposed to arsenic directly and those of future generations in a heritable manner, without directly altering the genome. Dysregulation of epigenetic processes could also contribute to vascular disease ([@b126-ehp-119-11]) and neurological disorders ([@b119-ehp-119-11]).

Many groups have directly examined the association of arsenic exposure on epigenetic phenomena; because the technologies used to study the various epigenetic modifications are developing rapidly, we believe that a review of current findings from the literature is warranted. We conducted a PubMed search (National Center for Biotechnology Information, U.S. National Library of Medicine, Bethesda, MD) through April 2010 and identified studies using variable keywords, such as "arsenic AND DNA methylation," "arsenic AND microRNA," "arsenic AND histone modification," and "arsenic AND epigentics AND epigenomics." Our goal was to include all the studies we could find, and thus the reference lists of the identified studies were also reviewed to identify other relevant studies. Although epigenetic alterations may contribute to effects of arsenic on both cancer and noncancer outcomes, in this article we summarize the recent *in vitro* and *in vivo* research findings on the potential role of arsenic-mediated epigenetic alterations in arsenic-induced toxicity and carcinogenicity. We discuss three major epigenetic mechanisms proposed to play roles in arsenic-induced carcinogenesis: altered DNA methylation, histone modification, and microRNA (miRNA) expression. We also propose future directions that can further inform our understanding of the epigenetic and overall mechanisms underlying the effects of arsenic.

Arsenic Exposure and DNA Methylation
====================================

DNA methylation is tightly regulated in mammalian development and is essential for maintaining the normal functioning of the adult organism ([@b103-ehp-119-11]). Altered DNA methylation has been associated with several human diseases ([@b98-ehp-119-11]). Global genomic DNA hypomethylation is a hallmark of many types of cancers ([@b32-ehp-119-11]), resulting in illegitimate recombination events and causing transcriptional deregulation of affected genes ([@b98-ehp-119-11]). In mammalian systems, DNA methylation occurs predominantly in cytosine-rich gene regions, known as CpG islands, and serves to regulate gene expression and maintain genome stability ([@b128-ehp-119-11]). DNA methyltransferases (DNMTs) are responsible for transferring a methyl group from the *S*-adenosyl methionine (SAM) cofactor to the cytosine nucleotide, producing 5′-methylcytosine and *S*-adenosyl homocysteine ([Figure 1](#f1-ehp-119-11){ref-type="fig"}) ([@b96-ehp-119-11]). Three different families of *DNMT* genes have been identified so far: *DNMT1*, *DNMT2*, and *DNMT3* ([@b99-ehp-119-11]).

Mechanisms of arsenic-induced changes in DNA methylation
--------------------------------------------------------

An association between arsenic-induced carcinogenesis and DNA methylation was proposed because arsenic methylation and DNA methylation both use the same methyl donor, SAM ([Figure 1](#f1-ehp-119-11){ref-type="fig"}). SAM is a coenzyme involved in \> 40 metabolic reactions that require methyl group transfers ([@b21-ehp-119-11]; [@b68-ehp-119-11]; [@b97-ehp-119-11]). Because SAM is the unique methyl group donor in each conversion step of biomethylation of arsenic, long-term exposure to arsenic may lead to SAM insufficiency and global DNA hypomethylation ([@b23-ehp-119-11]; [@b41-ehp-119-11]; [@b131-ehp-119-11]). Further, because SAM synthesis requires methionine, an essential amino acid in humans, dietary methyl insufficiency could exacerbate effects of arsenic on DNA methylation ([Figure 1](#f1-ehp-119-11){ref-type="fig"}) ([@b78-ehp-119-11]). Indeed, human exposure to arsenic often occurs in relatively resource-poor populations in developing countries that also may have low dietary intakes of methionine ([@b4-ehp-119-11]). In addition to its effect on SAM availability, arsenic can directly interact with DNMTs and inhibit their activities. Several studies have shown that arsenic exposure leads to a dose-dependent reduction of mRNA levels and activity of DNMTs both *in vitro* and *in vivo*, including *DNMT1*, *DNMT3A*, and *DNMT3B* ([@b2-ehp-119-11]; [@b27-ehp-119-11]; [@b39-ehp-119-11]; [@b97-ehp-119-11]).

Arsenic and global DNA hypomethylation
--------------------------------------

Global DNA hypomethylation is expected to result from arsenic exposure through both SAM insufficiency and reduction of *DNMT* gene expression ([@b97-ehp-119-11]). Arsenic exposure has been reported to induce DNA hypomethylation *in vitro* and in animal studies ([Table 1](#t1-ehp-119-11){ref-type="table"}). For example, rats ([@b120-ehp-119-11]) and mice ([@b18-ehp-119-11]; [@b86-ehp-119-11]; [@b125-ehp-119-11]) exposed to As^III^ for several weeks displayed global hepatic DNA hypomethylation. Similarly, exposure of fish to As^III^ for 1, 4, or 7 days resulted in sustained DNA hypomethylation compared with nonexposed fish ([@b6-ehp-119-11]). Studies in cell lines *in vitro* yielded similar results, with a reduction in global genomic DNA methylation resulting from As^III^ exposure ([Table 1](#t1-ehp-119-11){ref-type="table"}) ([@b10-ehp-119-11]; [@b23-ehp-119-11]; [@b97-ehp-119-11]; [@b107-ehp-119-11]; [@b131-ehp-119-11]). In contrast to the animal and *in vitro* findings, there are limited human population studies available. A cross-sectional study of 64 people reported by [@b71-ehp-119-11] indicated that exposure to arsenic-contaminated water (250--500 μg/L) was associated with global DNA hypermethylation. However, the participants in the highest estimated exposure group (\> 500 μg/L) had methylation levels that were comparable with those in the two lowest groups. The one possible reason for this inconsistency may be that the actual intake of arsenic into the body is different in the participants whose exposures were estimated based on the concentrations in their drinking water. In another well-designed nested case--control study, [@b92-ehp-119-11] assessed the relationship between arsenic and DNA methylation in 294 participants and observed a positive association between urinary arsenic and DNA hypermethylation. Plasma folate level apparently has a significant effect on the level of DNA methylation because a dose--response relation was evident only among participants with adequate folate levels (≥ 9 nmol/L) when estimates were stratified according to plasma folate level after controling for other factors. In a separate but closely related nested case--control study, [@b93-ehp-119-11] found that individuals with hypomethylation of peripheral blood leukocyte (PBL) DNA were 1.8 (95% confidence interval, 1.2--2.8) times more likely to have skin lesions 2 years later after adjusting for age, urinary arsenic, and other factors. [@b93-ehp-119-11] speculated that

> Adequate folate may be permissive for an adaptive increase in genomic methylation of PBL DNA associated with \[arsenic\] exposure, and that individuals who are similarly exposed but in whom the increase in genomic DNA methylation does not occur (or cannot be sustained) are at elevated risk for skin lesions.

Further studies are required to determine if exposure to As^III^ has differential effects on the status of DNA methylation across tissues, cells, and species.

Arsenic and gene promoter methylation
-------------------------------------

Although the effects of arsenic exposure on global genomic DNA methylation remain unclear, DNA hypomethylation or hypermethylation of promoters of some genes has been reported in human skin cancer ([@b17-ehp-119-11]) and bladder cancer ([@b20-ehp-119-11]; [@b75-ehp-119-11]) associated with arsenic exposure. It has also been observed in human cell lines ([@b16-ehp-119-11]; [@b38-ehp-119-11]; [@b52-ehp-119-11]; [@b77-ehp-119-11]), animal cell lines ([@b19-ehp-119-11], [@b118-ehp-119-11]), animals ([@b26-ehp-119-11]; [@b86-ehp-119-11]; [@b121-ehp-119-11]), and humans ([@b17-ehp-119-11]; [@b20-ehp-119-11]; [@b74-ehp-119-11]; [@b129-ehp-119-11]) exposed to arsenic ([Table 2](#t2-ehp-119-11){ref-type="table"}). Although this gene-specific effect observed in these studies could be due to study bias, because researchers examined only a small group of genes, the similar methylation pattern repeatedly reported in the same genes after arsenic exposure might also suggest that arsenic could selectively target specific genes. However, little is known about how DNA methylation is targeted to specific regions ([@b57-ehp-119-11]). Hypo- and hypermethylation of genes could mediate carcinogenesis through up-regulation of oncogene expression or down-regulation of tumor suppressor genes, respectively. Both observations have been reported. Hypomethylation of the promoter region of oncogenic *Hras1* and an elevated *Hras1* mRNA level was demonstrated in mice treated with sodium arsenite ([@b86-ehp-119-11]). Similar results on mRNA expression and promoter hypomethylation of *Hras1* and *c-myc* were also observed *in vitro* ([@b19-ehp-119-11]; [@b118-ehp-119-11]). The evidence has linked overexpression of *Esr1* (estrogen receptor 1) gene with estrogen-induced hepatocellular carcinoma in mice ([@b24-ehp-119-11]). Arsenic exposure leads to overexpression of the *Esr1* gene resulting from hypomethylation of its promoter region, indicating an association between overexpression of *Esr1* and arsenic hepatocarcinogenesis ([@b18-ehp-119-11]; [@b121-ehp-119-11]).

Dose-dependent hypermethylation at the promoter region of several tumor suppressor genes \[e.g., *p15*, *p16*, *p53*, and death-associated protein kinase (*DAPK*)\] was induced by arsenic exposure *in vitro* and *in vivo* ([@b11-ehp-119-11]; [@b17-ehp-119-11]; [@b38-ehp-119-11]; [@b77-ehp-119-11]; [@b129-ehp-119-11]). In a population-based study of human bladder cancer in 351 patients, *RASSF1A* and *PRSS3* promoter hypermethylation was positively associated with toenail arsenic concentrations, and promoter hypermethylation in both genes also was associated with invasive (vs. noninvasive low grade) cancer ([@b74-ehp-119-11]). This outcome was recapitulated in arsenic-induced lung cancer in A/J mice, in which the arsenic exposure reduced the expression of *RASSF1A* resulting from hypermethylation of its promoter region and was associated with arsenic-induced lung carcinogenesis ([@b26-ehp-119-11]). DAPK is a positive mediator of γ-interferon--induced programmed cell death and a tumor suppressor candidate. In a study of 38 patients with urothelial carcinoma, [@b20-ehp-119-11] reported hypermethylation of *DAPK* in 13 of 17 tumors in patients living in arsenic-contaminated areas compared with 8 of 21 tumors from patients living in areas not contaminated with arsenic. This hypermethylation of *DAPK* was also observed in an *in vitro* study when immortalized human uroepithelial cells were exposed to arsenic ([@b16-ehp-119-11]). The increase of DNA hypermethylation of promoter in *p16* was observed in arseniasis patients compared with people with no history of arsenic exposure ([@b129-ehp-119-11]). In another study [@b17-ehp-119-11] examined the methylation status of promoters in *p53* and *p16* in DNA extracted from peripheral lymphocytes and observed an increase of methylation in both *p53* and *p16* associated with an estimated arsenic exposure in a dose-dependent manner. However, this same study also showed that the subjects from the highest arsenic exposure group exhibited hypomethylation of both *p53* and *p16*. Chronic exposure to arsenic *in vitro* has been shown to induce malignant transformation in several human cell types ([@b10-ehp-119-11]; [@b131-ehp-119-11]) in which the alteration of DNA methylation level has been shown to be involved ([@b52-ehp-119-11], [@b53-ehp-119-11]; [@b131-ehp-119-11]).

Summary
-------

Arsenic does not fall into the classic model of carcinogenesis because it is not efficient at inducing point mutations or initiating and promoting the development of tumors in experimental animals. One likely mechanism by which arsenicals operate is through the disruption of normal epigenetic control at specific loci, which may result in aberrant gene expression and cancer ([@b3-ehp-119-11]; [@b124-ehp-119-11]). Although there is increasing evidence that arsenic exposure alters methylation levels in both global DNA and promoters of some genes, the current available studies are essentially descriptive and difficult to interpret because of the complexity of the study populations and limited information provided in the reports. Studies are needed that systematically investigate DNA methylation on a genomewide level in arsenic-exposed cell lines and in target tissues, such as exfoliated bladder cells, from well-characterized arsenic-exposed human populations, or in tumor tissue from arsenic-associated cancers. Such studies would help to clarify potential effects of arsenic exposure on DNA methylation and carcinogenesis.

Arsenic Exposure and Histone Modification
=========================================

Chromatin is structured within the cell nucleus in units called nucleosomes, in which DNA is packaged within the cell. The nucleosome core particle consists of stretches of DNA (\~ 146 bp) wrapped in left-handed superhelical turns around a histone octamer consisting of two copies each of the core histones H2A, H2B, H3, and H4 ([@b69-ehp-119-11]). Although H1 does not make up the nucleosome "bead," H1 plays a role in keeping in place the DNA that has wrapped around the nucleosome ([Figure 2](#f2-ehp-119-11){ref-type="fig"}). From a structural and functional perspective, histones have different characteristics depending on the number of amino acids and the number and type of covalent modifications in these residues. These covalent modifications, found in the tails of the histone chains, influence many fundamental biological processes including acetylation, methylation, phosphorylation, citrullination, ubiquitination, sumoylation, ADP ribosylation, deimination, and proline isomerization ([@b63-ehp-119-11]) ([Figure 2](#f2-ehp-119-11){ref-type="fig"}). To date, published studies on histone modifications and arsenic toxicity have focused on acetylation, methylation, and phosphorylation.

Histone acetylation
-------------------

Histone acetylation is a dynamic and reversible event ([@b40-ehp-119-11]), in which the acetylation status of lysine residues in the histone tail is regulated by two antagonistic enzyme classes, histone acetyltransferases (HATs) ([@b114-ehp-119-11]) and histone deacetylases (HDACs) ([@b25-ehp-119-11]). Using acetyl coenzyme A as an acetyl group donor, HATs enzymatically transfer a single acetyl group to the ɛ-amino group of specific lysine side chains within the histone's basic N-terminal tail region, whereas HDACs remove the acetyl group from the lysine residues.

Evidence for an association between altered histone acetylation and arsenic-induced toxicity continues to be strengthened. In the early 1980s, arsenic exposure was shown to significantly reduce histone acetylation in *Drosophila* ([@b5-ehp-119-11]). More recently, changes in histone H3 acetylation have been observed in association with As^III^- and MMA^III^-induced malignant transformation of human urothelial cells *in vitro*; these modifications apparently are arsenic specific because the co-occurring changes in both As^III^- and MMA^III^-induced malignant transformation are significantly more frequent than those occurring by random chance ([@b52-ehp-119-11]). Further, [@b52-ehp-119-11] reported DNA hypermethylation in a number of the hypoacetylated promoters identified in the study, suggesting that arsenic coordinately targets genes through dysregulation of different epigenetic mechanisms contributing to malignant transformation. Recently, we showed that the global level of H4K16 acetylation in human bladder epithelial cells was reduced in a dose- and time-dependent manner by both As^III^ and MMA^III^ treatment ([@b55-ehp-119-11]). Moreover, knockdown of *MYST1*, the gene responsible for H4K16 acetylation, resulted in increased cytotoxicity from arsenical exposure in human bladder epithelial cells, suggesting that H4K16 acetylation may be important for resistance to arsenic-induced toxicity.

Interestingly, As^III^ exposure has also been shown to induce elevated histone acetylation, which was reportedly responsible for the up-regulation of genes involved in apoptosis or the response to cell stress after exposure to arsenic ([@b65-ehp-119-11], [@b66-ehp-119-11]). This result probably is mediated by HDACs. As^III^ has been shown to inhibit *HDAC* genes that correlate with increased global histone acetylation ([@b95-ehp-119-11]). The level of inhibition is comparable with that of the well-known HDAC inhibitor trichostatin A ([@b31-ehp-119-11]). Together, these studies clearly provide evidence that histone acetylation is dysregulated by arsenic exposure, but further work is needed to understand the underlying mechanisms and to clarify the net effect of altered histone acetylation on arsenic-induced toxicity and carcinogenesis.

Histone methylation
-------------------

Like acetylation, histone methylation is also a reversible process. However, unlike acetylation, which occurs only on lysine residues at the histone tail, histone methylation occurs on both lysine and arginine residues ([@b76-ehp-119-11]; [@b123-ehp-119-11]). In mammals, histone methylation is usually found on histone H3 and H4, although it also occurs on H2A or H2B. Arginine methylation is catalyzed by the enzyme arginine *N*-methyltransferase ([@b123-ehp-119-11]), whereas lysine methylation is catalyzed by two different classes of proteins, the SET-domain--containing protein family and the non-SET-domain proteins DOT1/DOT1L ([@b76-ehp-119-11]). Histone methylation can occur in the monomethyl, symmetrical dimethyl, and asymmetrical dimethyl states and in the trimethyl group states, in contrast to the single acetyl group added during acetylation ([@b62-ehp-119-11]). Histone methylation was considered a static modification until recent years, when enzymes were found to be capable of antagonizing histone arginine methylation or directly removing a methyl group from a lysine residue of histone ([@b62-ehp-119-11]). These enzymes include peptidylarginine deiminase enzymes and amine oxidase-- and JmjC domain--containing histone demethylase enzymes.

Accumulating evidence implicates the aberrant loss or gain of histone methylation in tumorigenesis ([@b105-ehp-119-11]). [@b5-ehp-119-11] first reported that exposure to arsenic in *Drosophila* cells led to a complete abolishment of methylation of histones H3 and H4, and the effect on H3 was later confirmed by other investigators ([@b28-ehp-119-11], [@b29-ehp-119-11]). The response to arsenic exposure in the mammalian cell is more complex, and As^III^ treatment can lead to differential effects on the methylation of H3 lysine residues, including increased H3 lysine 9 dimethylation (H3K9me2) and H3 lysine 4 trimethylation (H3K4me3) and decreased H3 lysine 27 trimethylation (H3K27me3) ([@b134-ehp-119-11]). [@b133-ehp-119-11] showed that 1 μM arsenite significantly increased H3K4me3 after 24-hr or 7-day exposures in human lung carcinoma A549 cells. Importantly, H3K4me3 remained elevated, apparently inherited through cell division, 7 days after the removal of arsenite. Elevated H3K9me2, mediated by increased levels of histone methyltransferase G9a protein ([@b134-ehp-119-11]), correlates with transcriptional repression ([@b90-ehp-119-11]) and has been shown to be involved in the silencing of tumor suppressers in the cancer cell lines ([@b33-ehp-119-11]; [@b79-ehp-119-11]). However, data on the patterns of histone methylation induced by arsenic exposure are limited, and further studies are required to decipher the relationship between altered histone methylation and gene expression, as well as its effect on arsenic-induced carcinogenesis.

Histone phosphorylation
-----------------------

All four core histone proteins, H2A, H2B, H3, and H4, and the linker histone H1 can be posttranslationally modified by phosphorylation. Cyclin-dependent kinases are believed to be responsible for H1 phosphorylation ([@b117-ehp-119-11]). Several kinases are able to phosphorylate H2A and H2B, such as ataxia telangiectasia mutated for H2AX ([@b13-ehp-119-11]). Phosphorylation of H3 has been specifically implicated in cell cycle progression and regulation of gene expression ([@b46-ehp-119-11]). Similarly, phosphorylation of histone H4 (serine 1) increases during the cell cycle and is believed to be regulated by casein kinase 2 ([@b8-ehp-119-11]).

Histone phosphorylation may also contribute to arsenic-induced carcinogenesis. Although all four core histones (H2A, H2B, H3, and H4) are targets of protein kinases ([@b90-ehp-119-11]), the best-studied histone phosphorylation event is that of H2AX, a form of H2A that represents up to 25% of the total H2A pool in mammals. [@b135-ehp-119-11] demonstrated that arsenic trioxide induces apoptosis by up-regulation of phosphorylated H2AX and may be one of the mechanisms by which arsenic trioxide acts as an antineoplastic agent ([Figure 2](#f2-ehp-119-11){ref-type="fig"}). Little is known about histone phosphorylation and arsenic carcinogenesis. Studies have suggested that H3 phosphorylation induced by arsenic exposure might be responsible for the up-regulation of the oncogenes c-*fos* and c-*jun* ([@b66-ehp-119-11]) and induction of a protoapoptotic factor, caspase 10 ([@b65-ehp-119-11]). Nickel, another important metal with epigenetic effects, has been shown to induce phosphorylation of histone 3, specifically H3S10 (serine 10) via the activation of the JNK/SAPK (c-jun N-terminal kinase/stress-activated protein kinase) pathway ([@b60-ehp-119-11]). Because arsenite exposure is known to activate JNK and p38/Mpk2 kinase by inhibition of the corresponding protein phosphatases ([@b15-ehp-119-11]), phosphorylation of histone H3 via the JNK/SAPK pathway might be a common mechanism of metal-induced histone modification.

Different types of histone modifications have been shown to affect gene regulation and expression in a coordinated manner. For example, *WNT5A* gene expression is up-regulated in As^III^- and MMA^III^-induced malignant transformation in uroepithelial cells in association with the enrichment of permissive histone modifications and reduction of repressive modifications in the *WNT5A* promoter region ([@b54-ehp-119-11]). Two modifications of histone H3, dimethylation of H3K4 and acetylation of H3K9 and H3K14, are associated with transcriptional competency, whereas the other two modifications of histone H3, trimethylation of H3K27 and dimethylation of H3K9, are correlated with transcriptional repression ([@b90-ehp-119-11]).

Summary
-------

Although we are still in the early stages of elucidating the association between histone modifications induced by arsenic and their effects on arsenic carcinogenicity, newly available techniques such as mass spectrometry (MS)-based histone modification analysis and genomewide sequencing offer the potential to systematically characterize the altered histone modifications induced by arsenicals and the subsequent changes in gene expression.

Arsenic Exposure and miRNA Expression
=====================================

In the past few years, several laboratories have discovered a small class of non-protein-coding RNAs, called microRNAs (miRNAs), that participate in diverse biological regulatory events and are transcribed mainly from non-protein-coding regions of the genome ([@b9-ehp-119-11]; [@b42-ehp-119-11]). More than 700 human miRNAs have been identified to date, as documented in the miRBase database (Release 14; [@b80-ehp-119-11]), and it is predicted that many more exist. Each miRNA is thought to target several hundred genes, and as many as 30% of mammalian genes are regulated by miRNA ([@b64-ehp-119-11]). miRNAs deactivate gene expression by binding to the 3′-untranslated region of mRNA with incomplete base pairing ([@b122-ehp-119-11]). The exact mechanisms by which expression is repressed are still under investigation but may include the inhibition of protein synthesis, the degradation of target mRNAs, and the translocation of target mRNAs into cytoplasmic processing bodies ([@b50-ehp-119-11]). Because of the suppressive effect of miRNA on gene expression, a reduction or elimination of miRNAs that target oncogenes could result in the inappropriate expression of those oncoproteins; for example, [@b56-ehp-119-11] have shown that *RAS* oncogene is regulated by the let-7 miRNA family. Conversely, the amplification or overexpression of miRNAs that have a role in regulating the expression of tumor suppressor genes could reduce the expression of such genes. A prime example of this is the observation of the miR-34 family on the p53 tumor suppressor pathway ([@b43-ehp-119-11]).

Altered miRNA expression and arsenic exposure
---------------------------------------------

Despite the significant progress made toward understanding the biogenesis and mechanisms of action of miRNA, much less is known about the effect of environmental exposures, especially carcinogens such as arsenic, on miRNA expression. Several studies have shown that exposure to exogenous chemicals can alter miRNA expression ([@b59-ehp-119-11]; [@b94-ehp-119-11]; [@b108-ehp-119-11]). *In vitro* exposure of cells to iron sulfate or aluminum sulfate, which generate reactive oxygen species (ROS), led to the up-regulation of a specific set of miRNAs, including miR-9, miR-125b, and miR-128 ([@b70-ehp-119-11]). ROS generation resulting from arsenic exposure is thought to play a large role in arsenic- induced carcinogenesis and toxicity ([@b35-ehp-119-11]; [@b45-ehp-119-11]) and could potentially alter these miRNAs in a similar manner. [@b73-ehp-119-11] examined the roles that arsenic and folate deficiency play in miRNA expression; these authors found that human lymphoblast TK6 cells that had been treated with sodium arsenite and cells that had been grown in folate-deficient media over a 6-day period showed similarly altered expression of five miRNAs compared with untreated controls, suggesting a common mechanism of dysregulation. One such potential mechanism is aberrant DNA methylation occurring as a result of SAM depletion ([@b14-ehp-119-11]; [@b68-ehp-119-11]), which arises under conditions of arsenic exposure and folate deficiency. However, [@b14-ehp-119-11] found no significant decrease in global methylation in the treated compared with the control groups, suggesting more subtle or targeted effects. The induced changes in miRNA expression were not stable and returned to baseline levels upon removal of the stress conditions, suggesting that chronic exposure may be necessary to permanently alter expression of miRNAs ([@b73-ehp-119-11]). Arsenic trioxide, a treatment option for acute promyelocytic leukemia (APL) ([@b132-ehp-119-11]), induces the relocalization and degradation of the nuclear body protein promyelocytic leukemia (PML) protein, as well as the degradation of PML--retinoic acid receptor-α (PML-RARα) in APL cells ([@b109-ehp-119-11]). APL patients treated with all-*trans* retinoic acid release a group of miRNAs transcriptionally repressed by the APL-associated PML-RAR oncogene ([@b102-ehp-119-11]), suggesting that arsenicals may produce similar effects on miRNA expression in APL patients.

Summary
-------

Overall, these studies show that environmental carcinogen exposures can lead to altered miRNA expression profiles, which may be associated with the process of carcinogenesis. Further studies are necessary to clarify whether chronic exposure to arsenic is capable of altering miRNA expression and what biological effects are related to the altered miRNA expression.

Epigenomic Approach Proposed for Future Studies
===============================================

Emerging evidence suggests that arsenic acts through several epigenetic mechanisms. The characterization of genomewide patterns of DNA methylation, posttranslational histone modification, and miRNA expression after arsenic exposure *in vitro* and *in vivo* represents a new frontier toward our understanding of the mechanisms of arsenic toxicity and carcinogenesis. Emerging epigenomic technologies such as chromatin immunoprecipitation (ChIP)-on-chip and ChIP sequencing (ChIP-seq), global methylation, and miRNA microarrays, as well as whole genome DNA sequencing platforms, will facilitate these efforts ([@b106-ehp-119-11]). ChIP-on-chip and ChIP-seq, used primarily to determine how proteins interact with DNA, have the potential to clarify how epigenetic changes, particularly histone modifications, induced by arsenic exposure regulate gene expression ([@b88-ehp-119-11]). MS offers an unbiased approach to mapping the combinations of histone modifications and requires highly sensitive and precise mass measurements; for example, the difference in mass between trimethylation and acetylation is only 36 mDa. Using liquid chromatography--MS, we identified acetylation of H4K16 as a histone modification that is significantly reduced after arsenic treatment, especially with long-term exposure ([@b55-ehp-119-11]).

With the rapid development of array and sequencing-based DNA-methylation profiling technologies, global DNA methylation profiling has clearly come of age. Because epigenetic modifications alter gene expression but not gene sequence, transcriptomics may eventually allow the characterization of the expression profiles of epigenetically labile genes. Identification of the genes dysregulated through epigenetic mechanisms by arsenic exposure will further elucidate the associated biological processes and disease states. Proteomics using both conventional "bottom-up" and newer cutting-edge "top-down" MS approaches to detect labile posttranslational modifications that are often lost in conventional MS/MS experiments will allow further clarification of the resulting phenotype. The difference between these two approaches is that the materials introduced into the mass spectrometer are either peptides generated by enzymatic cleavage of one or many proteins in the "bottom-up" approach, or intact protein ions or large protein fragments in the "top-down" approach. Integration of epigenetic, transcriptomic, and proteomic data sets generated by these techniques will facilitate a more thorough understanding of the interplay of these processes under normal conditions and during arsenic exposure. Indeed, the importance of a comprehensive understanding of the epigenome has been recognized by the scientific community and is reflected in the National Institutes of Health (NIH) Roadmap Initiative ([@b85-ehp-119-11]) with the goal of developing comprehensive reference epigenome maps and new technologies for comprehensive epigenomic analyses.

Conclusion and Future Directions
================================

Although experiments in suitable model systems could complement the human studies, as discussed above, there may be differences between epigenetic effects in animals and humans and between various tissues and cell types. Thus, studies in human populations exposed to high levels of arsenic will be necessary to understand how individual differences in arsenic methylation and genetic background, as well as environmental factors such as diet and age, influence the epigenetic response to chronic arsenic exposure. Studies will also be required across various tissue and cell types to identify and validate the levels and patterns of epigenetic markers in these cells. Accessible tissues such as blood may not represent a good surrogate of target tissues such as bladder, kidney, and lung. High-resolution methylation data have shown that tissues have distinct epigenetic profiles ([@b22-ehp-119-11]; [@b49-ehp-119-11]), and aging and environmental exposures may alter methylation in a tissue-specific manner ([@b22-ehp-119-11]). Thus, epigenetic profiles from disease-relevant tissues such as exfoliated bladder cells from exposed and unexposed disease-free individuals could allow early effects to be identified. Such cells could also be analyzed from individuals with arsenic- and non--arsenic-associated cancers to identify arsenic-associated tumorigenic profiles. [@b100-ehp-119-11] showed that it may be possible to detect bladder cancer using gene expression signatures in exfoliated bladder urothelia. Similarly, the effects of inhaled arsenic on epigenetic profiles in bronchial airway epithelial cells could be examined in exposed and unexposed disease-free individuals and those with lung cancer, as was recently done using miRNA profiling for cigarette smoke exposure ([@b104-ehp-119-11]).

In conclusion, a comprehensive epigenomic approach may elucidate the mechanisms of arsenic-induced carcinogenesis. Such an approach would also facilitate the discovery of biomarkers of arsenic exposure and early effects, associated diseases and disease progression, and factors that confer susceptibility.
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![Simplified scheme of SAM synthesis and its involvement in arsenic and DNA methylation. The human arsenic metabolic pathway involves a series of methylation reactions; both arsenic metabolism and DNA methylation require SAM as the methyl donor. Here we show the intermediate steps of SAM synthesis and its involvement in the methylation of DNA and arsenic. Abbreviations: AS3MT, arsenic (+3 oxidation state) methyltransferase; ATP, Adenosine-5′-triphosphate; MAT1A, methionine adenosyltransferase I; MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase; PPP, tripolyphosphate.](ehp-119-11f1){#f1-ehp-119-11}

![Histone modifications affected by As^III^ and MMA^III^ exposure. Major posttranscriptional histone modifications of the nucleosome are listed on the left. Modifications of specific histone proteins reported in the literature as altered by arsenic exposure are shown on the right.](ehp-119-11f2){#f2-ehp-119-11}

###### 

Arsenic exposure and global DNA methylation.

  Model                                      Arsenical   Dose                         Time (weeks)   Global DNA methylation           References
  ------------------------------------------ ----------- ---------------------------- -------------- -------------------------------- --------------------------------------
  Human cells                                                                                                                         
                                                                                                                                      
   Prostate epithelial cell line RWPE-1      As^III^     5 μM                         16             Hypo                             [@b23-ehp-119-11]
   Prostate epithelial cell line RWPE-1      As^III^     5 μM                         29             Hypo                             [@b10-ehp-119-11]
   HaCaT keratinocytes                       As^III^     0.2 μM                       4              Hypo                             [@b97-ehp-119-11]
                                                                                                                                      
  Animal cells                                                                                                                        
                                                                                                                                      
   TRL 1215 rat liver epithelial cell line   As^III^     125--500 nM                  18             Hypo                             [@b131-ehp-119-11]
   V79-Cl3 Chinese hamster cells             As^III^     10 μM                        8              Hypo                             [@b107-ehp-119-11]
                                                                                                                                      
  Animal studies                                                                                                                      
                                                                                                                                      
   Goldfish                                  As^III^     200 μM                       1              Hypo                             [@b6-ehp-119-11]
   Fisher 344 rat                            As^III^     50 μg/g body weight          12             Hypo                             [@b120-ehp-119-11]
   129/SvJ mice                              As^III^     45 ppm                       49             Hypo                             [@b18-ehp-119-11]
   C3H mice                                  As^III^     85 ppm                       1.5            Hypo                             [@b121-ehp-119-11]
   C57BL/6J mice                             As^III^     2.6--14.6 μg/g body weight   18.5           Hypo                             [@b86-ehp-119-11]
   Homozygous Tg.AC mice                     As^III^     150 ppm                      17             Hypo                             [@b125-ehp-119-11]
                                             As^V^       200 ppm                                                                      
                                             MMA^V^      1,500 ppm                                                                    
                                             DMA^V^      1,200 ppm                                                                    
                                                                                                                                      
   Human subjects                                                                                                                     
                                                                                                                                      
                                             As^III^     2--250 μg/L                  NA             Hyper                            [@b92-ehp-119-11]; [@b71-ehp-119-11]
                                             As^III^     2--250 μg/L                  NA             Hypo (in skin lesion patients)   [@b93-ehp-119-11]

Abbreviations: Hyper, hypermethylated; Hypo, hypomethylated; NA, not available. See text for additional information on human subjects.

###### 

Arsenic exposure and gene-specific (promoter) methylation status.

                                                                                                                    Genes                                                          
  -------------------------------------- ---------- ---------------------------------------------------- ---------- ---------------------------------------- --------------------- --------------------
  Human cells                                                                                                                                                                      
                                                                                                                                                                                   
   UROtsa urothelial cells               As^III^    1 μM                                                 9          *DBC1*, *FAM83A*, *ZSCAN12*, *C1QTNF6*                         [@b52-ehp-119-11]
                                         MMA^III^   50 nM                                                                                                                          
   Uroepithelial SV-HUC-1 cells          As^III^    2, 4, 10 μM                                          24 or 52   *DAPK*                                                         [@b16-ehp-119-11]
   Myeloma cell line U266                As^III^    1, 2 μM                                              0.4        *P16*                                                          [@b38-ehp-119-11]
   Lung adenocarcinoma A549 cells        As^III^    0.08--2 μM                                           0.3        *P53*                                                          [@b77-ehp-119-11]
                                         As^V^      30--300 μM                                           0.3                                                                       
                                                                                                                                                                                   
  Animal cells                                                                                                                                                                     
                                                                                                                                                                                   
   Syrian hamster embryo cells           As^III^    3--10 μM                                             0.3                                                 c-*myc*, c-*Ha-ras*   [@b118-ehp-119-11]
                                         As^V^      50--150 μM                                           0.3                                                                       
   TRL 1215 rat liver epithelial cells   As^III^    125--500 nM                                          8 or 18                                             c-*myc*               [@b19-ehp-119-11]
                                                                                                                                                                                   
  Animal studies                                                                                                                                                                   
                                                                                                                                                                                   
   C57BL/6J mice                         As^III^    2.6--14.6 μg/g body weight                           18.5                                                c-*Ha-ras*            [@b86-ehp-119-11]
   A/J mice                              As^V^      100 ppm                                              74         *p16*, *RASSF1*                                                [@b26-ehp-119-11]
   C3H mice                              As^III^    85 ppm                                               1.4                                                 *ER*α                 [@b121-ehp-119-11]
                                                                                                                                                                                   
  Human subjects                                                                                                                                                                   
                                                                                                                                                                                   
                                         As^III^    NA                                                   NA         *DAPK*                                                         [@b20-ehp-119-11]
                                         As^III^    Variable[a](#tfn3-ehp-119-11){ref-type="table-fn"}   NA         *p53*, *P16*                                                   [@b17-ehp-119-11]
                                         As^III^    NA                                                   NA         *p16*                                                          [@b129-ehp-119-11]
                                         As^III^    Variable[b](#tfn4-ehp-119-11){ref-type="table-fn"}   NA         *RASSF1A*, *PRSS3*                                             [@b74-ehp-119-11]

Abbreviations: ERα, estrogen receptor α; Hyper, hypermethylated; Hypo, hypomethylated; NA, not available.

Study subjects were grouped based on historical arsenic concentration in drinking water, and the range of arsenic concentration in drinking water was \< 50 μg/L to \> 300 μg/L.

The estimated toenail arsenic concentration of study subjects was \< 0.01 μg/L to \> 50 μg/L.
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